Raymond James & Associates Has $2.52 Million Holdings in Integer Holdings Co. (NYSE:ITGR)

Raymond James & Associates cut its holdings in Integer Holdings Co. (NYSE:ITGR – Get Rating) by 16.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 40,548 shares of the medical equipment provider’s stock after selling 7,750 shares during the quarter. Raymond James & Associates’ holdings in Integer were worth $2,523,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Integer during the second quarter valued at about $844,000. Victory Capital Management Inc. boosted its stake in shares of Integer by 95.5% during the second quarter. Victory Capital Management Inc. now owns 867,575 shares of the medical equipment provider’s stock valued at $61,303,000 after purchasing an additional 423,888 shares in the last quarter. Bridgewater Associates LP boosted its stake in shares of Integer by 10.1% during the second quarter. Bridgewater Associates LP now owns 52,033 shares of the medical equipment provider’s stock valued at $3,677,000 after purchasing an additional 4,757 shares in the last quarter. Foundry Partners LLC acquired a new stake in shares of Integer during the third quarter valued at about $217,000. Finally, Park Avenue Securities LLC boosted its stake in shares of Integer by 19.8% during the second quarter. Park Avenue Securities LLC now owns 4,565 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 756 shares in the last quarter. 98.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ITGR. StockNews.com began coverage on Integer in a research report on Wednesday, October 12th. They set a “hold” rating for the company. KeyCorp lowered their price objective on Integer from $97.00 to $84.00 and set an “overweight” rating for the company in a research report on Thursday, October 6th. Finally, Benchmark lowered their price objective on Integer to $90.00 in a research report on Tuesday, November 1st.

Integer Trading Up 1.3 %

Shares of ITGR stock opened at $74.21 on Friday. The company has a market cap of $2.46 billion, a P/E ratio of 34.52 and a beta of 1.17. The stock has a 50 day simple moving average of $70.58 and a two-hundred day simple moving average of $66.75. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.74 and a current ratio of 2.80. Integer Holdings Co. has a fifty-two week low of $50.05 and a fifty-two week high of $88.58.

Integer (NYSE:ITGR – Get Rating) last issued its earnings results on Thursday, October 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.06. The business had revenue of $342.68 million during the quarter, compared to the consensus estimate of $343.15 million. Integer had a return on equity of 9.24% and a net margin of 5.47%. Research analysts forecast that Integer Holdings Co. will post 3.77 earnings per share for the current year.

Insider Buying and Selling at Integer

In other news, CEO Joseph W. Dziedzic acquired 4,000 shares of Integer stock in a transaction on Friday, December 16th. The stock was purchased at an average price of $61.95 per share, with a total value of $247,800.00. Following the completion of the purchase, the chief executive officer now owns 122,378 shares of the company’s stock, valued at approximately $7,581,317.10. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.01% of the company’s stock.

Integer Profile

(Get Rating)

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures.